Leukocyte telomere length is associated with complications of Type 2 diabetes mellitus

Diabetic Medicine

Volumn 28, Issue 11, 2011, Pages 1388-1394

  Testa, R ^a   Olivieri, F ^b,c   Sirolla, C ^a   Spazzafumo, L ^a   Rippo, M R ^b   Marra, M ^a   Bonfigli, A R ^a   Ceriello, A ^d   Antonicelli, R ^a   Franceschi, C ^e   Castellucci, C ^b   Testa, I ^a   Procopio, A D ^b,c  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c Centre of Clinical Pathology and Innovative Therapy   (Italy)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Diabetes complications; Telomeres

Indexed keywords

AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; REAL TIME POLYMERASE CHAIN REACTION; RISK; TELOMERE;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; HUMANS; LEUKOCYTES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; TELOMERE;

EID: 80054699397     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2011.03370.x     Document Type: Article

References (25)

1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.
2. Ceriello A, Kumar S, Piconi L, Esposito K, Giugliano D. Simultaneous control of hyperglycemia and oxidative stress normalizes endothelial function in type 1 diabetes. Diabetes Care 2007; 30: 649-654.
3. Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: UK Prospective Diabetes Study (UKPDS23). Br Med J 1998; 316: 823-828.
4. Riethman H. Human telomere structure and biology. Annu Rev Genomics Hum Gene 2008; 9: 1-19.
5. Artandi SE, Attardi LD. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005; 331: 881-890.
6. Gilley D, Herbert BS, Huda N, Tanaka H, Reed T. Factors impacting human telomere homeostasis and age-related disease. Mech Ageing Dev 2008; 129: 27-34.
7. Aviv A. The epidemiology of human telomeres: faults and promises. J Gerontol A Biol Sci Med Sci 2008; 63: 979-983.
8. Oeseburg H, de Boer RA, van Gilst WH, van der Harst P. Telomere biology in healthy aging and disease. Pflugers Arch 2010; 459: 259-268.
9. Adaikalakoteswari A, Balasubramanyam M, Mohan V. Telomere shortening occurs in Asian Indian Type2 diabetic patients. Diabet Med 2005; 22: 1151-1156.
10. Salpea KD, Talmud PJ, Cooper JA, Maubaret CG, Stephens JW, Abelak K et al. Association of telomere length with type2 diabetes, oxidative stress and UCP2 gene variation. Atherosclerosis 2010; 209: 42-50.
11. Zee RY, Castonguay AJ, Barton NS, Germer S, Martin M. Mean leukocyte telomere length shortening and type2 diabetes mellitus: a case-control study. Transl Res 2010; 155: 166-169.
12. Uziel O, Singer JA, Danicek V, Sahar G, Berkov E, Luchansky M et al. Telomere dynamics in arteries and mononuclear cells of diabetic patients: effect of diabetes and of glycemic control. Exp Gerontol 2007; 42: 971-978.
13. Verzola D, Gandolfo MT, Gaetani G, Ferraris A, Mangerini R, Ferrario F et al. Accelerated senescence in the kidneys of patients with type2 diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295: F1563-F1573.
14. Tentolouris N, Nzietchueng R, Cattan V, Poitevin G, Lacolley P, Papazafiropoulou A et al. White blood cells telomere length is shorter in males with type2 diabetes and microalbuminuria. Diabetes Care 2007; 30: 2909-2915.
15. Sampson MJ, Hughes DA. Chromosomal telomere attrition as a mechanism for the increased risk of epithelial cancers and senescent phenotypes in type2 diabetes. Diabetologia 2006; 49: 1726-1731.
16. Olivieri F, Lorenzi M, Antonicelli R, Testa R, Sirolla C, Cardelli M et al. Leukocyte telomere shortening in elderly Type2 DM patients with previous myocardial infarction. Atherosclerosis 2009; 206: 588-593.
17. Adaikalakoteswari A, Balasubramanyam M, Ravikumar R, Deepa R, Mohan V. Association of telomere shortening with impaired glucose tolerance and diabetic macroangiopathy. Atherosclerosis 2007; 195: 83-89.
18. Salpea KD, Humphries SE. Telomere length in atherosclerosis and diabetes. Atherosclerosis 2010; 209: 35-38.
19. Astrup AS, Tarnow L, Jorsal A, Lajer M, Nzietchueng R, Benetos A et al. Telomere length predicts all-cause mortality in patients with type1 diabetes. Diabetologia 2010; 53: 45-48.
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2007; 30: S42-S47.
21. Testa R, Bonfigli AR, Salvioli S, Invidia L, Pierini M, Sirolla C et al. The Pro/Pro genotype of the p53 codon72 polymorphism modulates PAI-1 plasma levels in ageing. Mech Ageing Dev 2009; 130: 497-500.
22. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002; 30: e47.
23. Ceriello A, Testa R. Antioxidant anti-inflammatory treatment in type2 diabetes. Diabetes Care 2009; 32: S232-236.
24. Atzmon G, Cho M, Cawthon RM, Budagov T, Katz M, Yang X et al. Evolution in health and medicine Sackler colloquium: genetic variation in human telomerase is associated with telomere length in Ashkenazi centenarians. Proc Natl Acad Sci U S A 2010; 107: 1710-1717.
25. Farzaneh-Far R, Lin J, Epel E, Lapham K, Blackburn E, Whooley MA. Telomere length trajectory and its determinants in persons with coronary artery disease: longitudinal findings from the heart and soul study. PLoS One 2010; 5: e8612.